Eli Lilly and Company & Novo Nordisk
35 shared events · Importance 4 · Last updated Aug 24, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Eli Lilly and Company: Main rival; maintains lead with Tirzepatide and Tirzepatide, but faces lawsuit and competition from oral Semaglutide.
Novo Nordisk: Central player; shares up 35% from March low, launching oral Semaglutide and suing Lilly, but faces competition and past profit warnings.
Aug 03, 2026 · 6 articles
Regulatory
Eli Lilly and Company: Eli Lilly and Company agreed to lower prices for its obesity drug Zepbound and will sell a starter dose for $299 a month, with additional doses up to $449, representing $50 reductions from current direct-to-patient prices. Its sales of Zepbound have tripled this year to over $9 billion.
Novo Nordisk: Novo Nordisk agreed to lower prices for its obesity drug Wegovy, making it more accessible to United States — Medicare and United States — Medicaid recipients and those paying directly. The company's spokesperson declined to provide specific details on pricing changes.
Nov 06, 2025 · 6 articles
Business
Eli Lilly and Company: Lilly leads GLP-1 sales in China and runs prominent awareness campaigns, though it paused its India campaign. Its Mounjaro is gaining patient demand.
Novo Nordisk: Novo launched the first once-weekly GLP-1 in China and is revamping its marketing under new president Cai Yan to better compete. Its market position is strong but faces increasing competition.
Aug 24, 2026 · 6 articles
Regulatory
Eli Lilly and Company: Eli Lilly and Company is a pharmaceutical company also facing lawsuits for its GLP-1 medications, Tirzepatide and Tirzepatide, which are alleged to have caused NAION. The company is accused of failing to warn consumers about these risks.
Novo Nordisk: Novo Nordisk is a pharmaceutical company facing multiple lawsuits alleging that its GLP-1 medications, Semaglutide and Semaglutide, caused NAION and that the company failed to adequately warn consumers about these risks. This could lead to significant financial and reputational damage.
May 22, 2026 · 7 articles
Business
Eli Lilly and Company: Eli Lilly and Company is a major competitor to Novo Nordisk in the weight-loss and diabetes drug market, with its drug Zepbound gaining market share against Novo Nordisk's Wegovy.
Novo Nordisk: Novo Nordisk announced significant job cuts and a revised profit outlook due to increased competition and slowing sales of its key weight-loss and diabetes drugs. The company aims to simplify its structure and reallocate resources for future growth.
Sep 10, 2025 · 6 articles
Business
Eli Lilly and Company: Eli Lilly and Company's drug Tirzepatide has been a strong competitor to Semaglutide in India, prompting Novo Nordisk to cut prices. Eli Lilly and Company has gained significant market share.
Novo Nordisk: Novo Nordisk cut the price of its weight-loss drug Semaglutide in India to compete with Eli Lilly and prepare for generic competition, aiming to increase market share and accessibility.
Nov 11, 2025 · 6 articles
Business
Eli Lilly and Company: Eli Lilly and Company faces increased competition with Novo Nordisk's Wegovy pill launch, potentially impacting its market dominance in weight-loss drugs. Its shares fell following the announcement.
Novo Nordisk: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Jan 05, 2026 · 7 articles
Domestic
Eli Lilly and Company: Eli Lilly and Company's drug, Tirzepatide, is also included in France's reimbursement plan, which will expand its market reach within the European Union.
Novo Nordisk: Novo Nordisk's drugs, Semaglutide and Tirzepatide, are among those that will be reimbursed in France, leading to increased market access and sales for the company in Europe. The company's General Manager and CEO welcomed the decision.
May 28, 2026 · 6 articles
Tech
Eli Lilly and Company: Eli Lilly and Company>>> produces GLP-1 drugs like Zepbound, Mounjaro, and Trulicity, which are showing potential benefits in cancer prevention and treatment.
Novo Nordisk: Novo Nordisk>>> produces GLP-1 drugs like Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
Tech
Eli Lilly and Company: Eli Lilly and Company produces Tirzepatide and Tirzepatide, which are GLP-1 agonist drugs. The study's findings on rapid weight regain after stopping medication could affect the perceived long-term efficacy and market demand for their products.
Novo Nordisk: Novo Nordisk produces Semaglutide and Semaglutide, which are GLP-1 agonist drugs. The research indicates that patients regain weight quickly after discontinuing these medications, potentially impacting long-term sales and cost-effectiveness assessments by health systems.
Jan 08, 2026 · 6 articles
Business
Eli Lilly and Company: Eli Lilly and Company is a leading pharmaceutical company with strong balance sheets, enabling it to be a major acquirer in the current M&A wave. It is also facing patent expirations on some of its blockbuster drugs.
Novo Nordisk: Novo Nordisk has shown a more aggressive M&A approach following recent CEO transitions and has been advised on recent deals, indicating its participation in the acquisition spree.
May 01, 2026 · 6 articles
Tech
Eli Lilly and Company: Manufacturer of exenatide, another GLP-1 drug studied for PMOS; potential new indication could boost sales.
Novo Nordisk: Manufacturer of semaglutide, the GLP-1 drug tested in the PMOS trials; positive results could expand its approved indications and market.
Aug 15, 2026 · 12 articles
Regulatory
Eli Lilly and Company: Eli Lilly's Zepbound is another GLP-1 drug involved; the study could prompt regulatory actions that impact its distribution.
Novo Nordisk: Novo Nordisk's Wegovy is one of the GLP-1 drugs being prescribed via telehealth; the study may lead to stricter oversight that could affect sales.
Jul 07, 2026 · 6 articles
Business
Eli Lilly and Company: Eli Lilly manufactures Mounjaro and Zepbound, GLP-1 drugs included in the study. The findings could enhance the perceived economic value of its products.
Novo Nordisk: Novo Nordisk manufactures Ozempic and Wegovy, key GLP-1 drugs studied. Positive study results may support continued strong sales and market growth.
Jul 21, 2026 · 6 articles
Regulatory
Eli Lilly and Company: Eli Lilly competes with Novo Nordisk in India's obesity-drug market with Mounjaro; the approval may intensify competition.
Novo Nordisk: Novo Nordisk is the drug manufacturer; the approval expands Wegovy's indication in India, potentially increasing sales and market share in the obesity and metabolic disease market.
Jul 17, 2026 · 13 articles
Tech
Eli Lilly and Company: Manufacturer of tirzepatide (Mounjaro, Zepbound); similar impact as Novo Nordisk.
Novo Nordisk: Manufacturer of semaglutide (Ozempic, Wegovy); study may raise safety concerns but risk is small.
Jul 14, 2026 · 6 articles
Tech
Eli Lilly and Company: Manufacturer of tirzepatide (Mounjaro, Zepbound); similar potential negative impact on product perception due to hair loss association.
Novo Nordisk: Manufacturer of semaglutide (Ozempic, Wegovy); the study may negatively impact perception of its GLP-1 products, though low absolute risk limits damage.
Jul 22, 2026 · 6 articles
Business
Eli Lilly and Company: Eli Lilly is another major GLP-1 manufacturer (Zepbound) and has introduced employer-focused programs to expand coverage. The bank's spending and industry trends benefit Lilly's market position.
Novo Nordisk: Novo Nordisk is a key manufacturer of GLP-1 drugs (Ozempic, Wegovy) covered by Bank of America. The bank's spending and broader employer adoption support Novo Nordisk's revenue growth, though pricing pressures remain.
Aug 05, 2026 · 6 articles
Business
Eli Lilly and Company: Eli Lilly and Company is a competitor in the Indian weight-loss drug market with its product Mounjaro, which has seen greater uptake than Novo Nordisk's Wegovy.
Novo Nordisk: Novo Nordisk partnered with Emcure Pharma to expand the distribution and marketing of its weight-loss drug semaglutide in India under the brand Poviztra, aiming to reach a wider population.
Nov 10, 2025 · 6 articles
Business
Eli Lilly and Company: Eli Lilly competes with Novo Nordisk in the obesity treatment market, but this launch is focused on diabetes.
Novo Nordisk: Novo Nordisk launched Awiqli, its once-weekly insulin, in India, enhancing its product portfolio and competitive edge in the diabetes market.
Jul 09, 2026 · 21 articles
Business
Eli Lilly and Company: Eli Lilly and Company is one of the healthcare leaders whose contracts were added to Phemex's TradFi ecosystem, making its assets available for 24/7 trading to Phemex users.
Novo Nordisk: Novo Nordisk is a healthcare leader whose contracts were integrated into Phemex's TradFi offering, allowing Phemex users to trade its assets continuously.
Jun 03, 2026 · 6 articles
Domestic
Eli Lilly and Company: Eli Lilly and Company>>> is one of the pharmaceutical companies participating in the TrumpRx program, agreeing to reduce prices on certain medications.
Novo Nordisk: Novo Nordisk>>> is participating in the TrumpRx program, agreeing to reduce prices on popular GLP-1 weight-loss medications.
Jun 06, 2026 · 8 articles
Tech
Eli Lilly and Company: Greta Duréel has consulted for Eli Lilly, but no direct impact from this study.
Novo Nordisk: Greta Duréel has consulted for Novo Nordisk, but no direct impact from this study.
Aug 12, 2026 · 6 articles
Regulatory
Novo Nordisk: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
+ 5 more events
View on Dashboard
ERGEN INTELLIGENCE
Explore this relationship live
Track how Eli Lilly and Company and Novo Nordisk interact across events, view sentiment trends, and discover connected entities.
Open Dashboard